Alan F Schatzberg MD
Director, Stanford Mood Disorders Center. Professor, Department of Psychiatry and Behavioral Sciences Stanford University Medical Center.
Join to view full profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-498-5710
Fax+1 650-498-5294
Dr. Schatzberg is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Psychiatry, 1969 - 1972
Lenox Hill Hospital-Northwell HealthInternship, Transitional Year, 1968 - 1969
New York University School of MedicineClass of 1968
Certifications & Licensure
MA State Medical License 1969 - 2027
CA State Medical License 1974 - 2026
American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
- America's Top Doctors Castle Connolly, 2002-2014
Clinical Trials
Publications & Presentations
PubMed
- 1 citationsBifunctional Modulation of NMDA and Opioid Receptors in Ketamine Reinforcement and Misuse: Implications for Substance Use Disorder Treatment.Marjorie R Levinstein, Ingrid Schoenborn, Peter Manza, Alan F Schatzberg, Carlos A Zarate Jr
Biological Psychiatry. 2026-08-01 - 1 citationsGeneral Anesthesia and Discrete Components of Ketamine Neurophysiology.Ben Deverett, Duan Li, Theresa R Lii, Phillip E Vlisides, Vijay Tarnal
JAMA Psychiatry. 2026-06-01 - 4 citationsLow-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.Jason M Tucciarone, Igor D Bandeira, Christine Blasey, Ian H Kratter, Jarrod Ehrie
The American Journal of Psychiatry. 2026-06-01
Journal Articles
- Splice-Break: Exploiting an RNA-Seq Splice Junction Algorithm to Discover Mitochondrial DNA Deletion Breakpoints and Analyses of Psychiatric DisordersFrancis S Lee, Alan F Schatzberg, Jack D Barchas, Virginia Kimonis, Elizabeth C Chao, Nucleic Acids Research
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
- American Psychiatric Association PublishingAlan Schatzberg, MD, National Institutes of Health
Press Mentions
June 2026: Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled TrialJune 1st, 2026- ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025November 7th, 2025
- After Quitting Antidepressants, Some People Suffer Surprising, Lingering SymptomsJuly 9th, 2025
Grant Support
- A Biobehavioral Research Training GrantSTANFORD UNIVERSITY1994–2030
- The Career Development Institute for PsychiatryUNIVERSITY OF PITTSBURGH AT PITTSBURGH2011–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
